CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤克星——CAR-T 细胞治疗「导弹」将射向何方？
英文原题：Tumor buster - where will the CAR-T cell therapy 'missile' go?
查看英文原题
Tumor buster - where will the CAR-T cell therapy 'missile' go?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
基于基因编辑技术的嵌合抗原受体（CAR）T细胞治疗，是人类癌症个体化免疫治疗的一项重要突破。该策略通过基因修饰使T细胞靶向肿瘤特异性抗原、攻击特定癌细胞，并在一定程度上绕过肿瘤细胞逃避凋亡机制。这一方法已广泛用于治疗血液系统疾病，但治疗实体瘤的效果并不理想。肿瘤抗原逃逸、治疗相关毒性和免疫抑制性肿瘤微环境（TME）限制了其应用。靶点选择是决定接受此类治疗患者预后的最关键因素。本文全面总结临床上已使用或显示良好潜力的所有治疗靶点，综述CAR-T 细胞治疗不同癌症的临床试验、应用、研究前沿和局限，并探讨遇到次优肿瘤相关抗原（TAA）或TAA丢失时的应对策略。此外，还强调CAR-T 细胞疗法在癌症免疫治疗中的重要性。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic modification to enable T cells to target tumor-specific antigens, attack specific cancer cells, and bypass tumor cell apoptosis avoidance mechanisms to some extent.
This method has been extensively used to treat hematologic diseases, but the therapeutic effect in solid tumors is not ideal. Tumor antigen escape, treatment-related toxicity, and the immunosuppressive tumor microenvironment (TME) limit their use of it. Target selection is the most critical aspect in determining the prognosis of patients receiving this treatment. This review provides a comprehensive summary of all therapeutic targets used in the clinic or shown promising potential.
We summarize CAR-T cell therapies' clinical trials, applications, research frontiers, and limitations in treating different cancers.
We also explore coping strategies when encountering sub-optimal tumor-associated antigens (TAA) or TAA loss.
Moreover, the importance of CAR-T cell therapy in cancer immunotherapy is emphasized.
论文信息
- 作者
- Qu C、Zhang H、Cao H、Tang L、Mo H、Liu F、Zhang L、Yi Z
- 第一作者单位
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.China
- 通讯作者单位
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. chengquan@csu.edu.cn.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Molecular cancer2022 Oct 19
- 原文标识
- PubMed 36261831 · DOI 10.1186/s12943-022-01669-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →